Opus Genetics公司近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对0.75%酚妥拉明滴眼液所提交的补充新药申请（sNDA）。该药物旨在用于治疗老花眼，标志着公司在眼科治疗领域取得重要进展。
Opus Genetics公司近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对0.75%酚妥拉明滴眼液所提交的补充新药申请（sNDA）。该药物旨在用于治疗老花眼，标志着公司在眼科治疗领域取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.